Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
PYC Therapeutics Limited ( (AU:PYC) ) has issued an update.
PYC Therapeutics Limited has initiated a global Phase 1b clinical trial, known as the MYRTLE study, for its investigational drug PYC-001, aimed at treating Autosomal Dominant Optic Atrophy (ADOA). The study will assess the safety, tolerability, and efficacy of repeat dosing of PYC-001, with initial dosing already administered to the first patient. This trial marks a significant step in establishing clinical proof of concept for PYC-001, potentially leading to a registrational study and offering hope for patients with no current treatment options.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is a precision medicine company focused on developing treatments for genetic diseases with no existing options. The company is advancing three clinical-stage drug development programs, including PYC-001, targeting Autosomal Dominant Optic Atrophy (ADOA), a blinding eye disease affecting 1 in 35,000 people.
Average Trading Volume: 782,282
Technical Sentiment Signal: Buy
Current Market Cap: A$699.9M
For an in-depth examination of PYC stock, go to TipRanks’ Overview page.